News

Public · Published

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics reported third-quarter 2026 revenue of $340.5 million, up from $256.1 million in the second quarter. Korlym and authorized generic revenue rose 19% to $249.1 million, while Lifyorli revenue increased 92% to $91.4 million. Net income was $126.8 million, and the company reiterated its 2026 revenue guidance of $1.1–$1.2 billion.

Published:

Updated:

What happened

Corcept Therapeutics reported third-quarter 2026 revenue of $340.5 million, up from $256.1 million in the second quarter. Korlym and authorized generic revenue rose 19% to $249.1 million, while Lifyorli revenue increased 92% to $91.4 million. Net income was $126.8 million, and the company reiterated its 2026 revenue guidance of $1.1–$1.2 billion.

Confirmed

Global impact / market context

Higher sales of both Korlym and Lifyorli drove quarterly revenue growth, while net income also increased from the prior quarter. If these products continue gaining patients and prescribers, they could support the company’s stated 2026 revenue outlook; operating expenses also rose, so sales growth alone does not show how costs will develop.

Analyst inference

The results point to two sources of reported growth: Korlym and authorized generic sales, and newer Lifyorli sales in ovarian cancer. Management cited greater awareness of Cushing’s syndrome and broad Lifyorli uptake, but the article provides no comparison with analyst expectations or share-price reaction.

Analyst inference

What to watch

  1. Watch whether the next reported results show continued growth in Korlym and authorized generic revenue, which reached $249.1 million this quarter, and whether operating expenses keep rising. Analyst inference
  2. Track Lifyorli prescriptions and revenue after more than 2,300 patients received it and over 1,700 physicians prescribed it since its April 1 launch, as reported. Confirmed
  3. Compare future revenue with the reiterated 2026 guidance of $1.1–$1.2 billion; results below that range could signal slower growth than management currently expects. Analyst inference

Evidence

  • Original source link unavailable